跳至主要内容
临床试验/2026-527114-23-00
2026-527114-23-00招募中2 期

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

Ovid Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
12
试验地点
1
主要终点
Change from Baseline in standardized photosensitivity range (SPR) on pre-dose Day 1 (placebo) to post-dose OV329 on several days

研究概览

简要总结

To evaluate the pharmacodynamic effect of OV329 on the IPS-induced PPR in participants with epilepsy, both after single oral dosing and after repeated dosing.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Male or female participants aged 18 to 65 years at the time of consent
  • Participants with a diagnosis and history of epilepsy (see exceptions in Exclusion Criteria).
  • Participants with a reproducible IPS-induced PPR of at least 4 points on a frequency assessment scale at Screening and Baseline.

排除标准

  • Participants with a history of non-epileptic seizures (e.g., metabolic or pseudo-seizures).
  • Participants with a diagnosis of Classical juvenile myoclonus epilepsy characterized by exclusively or predominantly early morning myoclonic seizures, as assessed by the investigator
  • Current use of vagus nerve stimulator or responsive neurostimulation is not permitted.
  • Participants who are taking or have taken OV329 as concomitant therapy within the last 3 months in other OV329 studies.

研究组 & 干预措施

OV329, OV329

Test

干预措施: OV329 (Drug)

结局指标

主要结局

Change from Baseline in standardized photosensitivity range (SPR) on pre-dose Day 1 (placebo) to post-dose OV329 on several days

Change from Baseline in standardized photosensitivity range (SPR) on pre-dose Day 1 (placebo) to post-dose OV329 on several days

次要结局

未报告次要终点

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Julia Tsai

Scientific

Ovid Therapeutics Inc.

研究点 (1)

Loading locations...

相似试验